Gastroenteropancreatic Neuroendocrine Tumor Clinical Trial
Official title:
A Phase 3, Single-arm, Open-label, Multicentre Study to Assess the Efficacy and Safety of Deep Subcutaneous Injections of Lanreotide Autogel® 120 mg Administered Every 28 Days in Chinese Participants With Unresectable, Locally Advanced or Metastatic Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs)
This study will be conducted to support the registration of the lanreotide Autogel 120 mg formulation in China for the treatment of GEP-NETs and treatment of clinical symptoms of NETs. The study will include a screening period of up to 4 weeks followed by a 48-week intervention period. After completion of the main study period, approximately five participants will continue in a self/partner injection cohort with lanreotide Autogel 120 mg every 28 days for 24 weeks.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06155318 -
68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours
|
||
Terminated |
NCT01994213 -
A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
|
Phase 2 | |
Active, not recruiting |
NCT03980925 -
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
|
Phase 2 | |
Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05064150 -
Neuroendocrine Tumors - Patient Reported Outcomes
|
||
Active, not recruiting |
NCT04727723 -
Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
|
||
Recruiting |
NCT06256705 -
Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort
|
N/A | |
Active, not recruiting |
NCT05477576 -
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
|
Phase 3 | |
Recruiting |
NCT04609592 -
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
|
Phase 1 | |
Recruiting |
NCT05701241 -
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
|
Phase 4 | |
Completed |
NCT02948946 -
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
|
||
Withdrawn |
NCT04915144 -
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
|
Phase 2 | |
Recruiting |
NCT04986085 -
Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
|
||
Active, not recruiting |
NCT05262556 -
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
|
Phase 1 | |
Completed |
NCT03017690 -
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
|